Overview
The Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 to curb misuse of medicinal products that contain high levels of ethyl alcohol. Formulations with more than 12% v/v alcohol and volumes over 30 mL will no longer enjoy the exemption under Schedule K. Instead, they will be placed under Schedule H1, requiring a licence under the Drugs and Cosmetics Act, 1940.
Key Developments (July 10 2026)
- All drug formulations containing >12% v/v ethyl alcohol in quantities >30 mL lose Schedule K exemption.
- These products are now classified under Schedule H1, mandating sale only on a registered medical practitioner’s prescription.
- Manufacturers and distributors must obtain a licence as per the Drugs and Cosmetics Act, 1940 and maintain detailed records.
- The amendment aims to prevent diversion of high‑alcohol medicines for intoxication while preserving legitimate therapeutic use.
Important Facts
• The exemption previously covered tinctures of cardamom, ginger and other aromatic preparations, some containing up to 80–90% v/v alcohol.
• State governments had raised concerns about potential misuse, prompting the central amendment.
• The Gazette Notification detailing the changes is available at egazette.gov.in.
Relevance for UPSC Aspirants
This amendment touches upon several GS topics:
- GS2 – Polity & Governance: Role of the Ministry of Health in drug regulation and inter‑governmental coordination.
- GS3 – Economy & Public Health: Impact of stricter licensing on the pharmaceutical supply chain and public safety.
- GS4 – Ethics: Balancing access to essential medicines with the need to prevent substance abuse.
Way Forward
To ensure effective implementation, the government should:
- Strengthen monitoring mechanisms at the state level for compliance with Schedule H1 requirements.
- Conduct awareness programmes for pharmacists and medical practitioners about the new licensing norms.
- Periodically review the list of high‑alcohol formulations to address emerging misuse patterns.
These steps will help create a safer pharmaceutical environment while maintaining access for genuine therapeutic needs.